ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Doxorubicin ADVAGEN, is now approved in Singapore.

“We are thankful to receive our first registration approval for 2022 with Doxorubicin, and we will aim to continue delivering safe, effective, and affordable treatment options for all in a timely manner for the year ahead.” – Soo, Regulatory Affairs.